TBPH FY 2021 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M-23.0% YoY

Gross Profit

-$138M-250.1% margin

Operating Income

-$258M-466.1% margin

Net Income

-$199M-360.6% margin

EPS (Diluted)

$-2.87

Cash Flow

Operating Cash Flow

-$208M

Free Cash Flow

-$211M

Stock-Based Comp.

$62M

Balance Sheet

Total Assets

$375M

Total Liabilities

$713M

Stockholders' Equity

-$339M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$72M	-23.0%
Gross Profit	-$138M	$72M	-292.5%
Operating Income	-$258M	-$298M	+13.4%
Net Income	-$199M	-$278M	+28.3%